Literature DB >> 18321704

Synthesis and evaluation of 3- and 7-substituted geranylgeranyl pyrophosphate analogs.

Michelle Maynor1, Sarah A Scott, Emily L Rickert, Richard A Gibbs.   

Abstract

Protein prenyl transferases have been a focus of anti-cancer drug discovery in recent years due to their roles in post-translational modification of small GTP binding proteins. Attention is now turning to the development of GGTase I inhibitors. Here, we present the synthesis and biological evaluation of four GGPP analogs versus mammalian GGTase I and the discovery that 7-allyl GGPP is a surprisingly efficient GGTase I substrate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321704      PMCID: PMC2376209          DOI: 10.1016/j.bmcl.2008.02.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I.

Authors:  Hairuo Peng; Dora Carrico; Van Thai; Michelle Blaskovich; Cynthia Bucher; Erin E Pusateri; Said M Sebti; Andrew D Hamilton
Journal:  Org Biomol Chem       Date:  2006-03-21       Impact factor: 3.876

2.  Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity.

Authors:  Heather L Hartman; Katherine A Hicks; Carol A Fierke
Journal:  Biochemistry       Date:  2005-11-22       Impact factor: 3.162

3.  Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy.

Authors:  Panagiotis A Konstantinopoulos; Athanasios G Papavassiliou
Journal:  Trends Pharmacol Sci       Date:  2006-12-05       Impact factor: 14.819

4.  Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.

Authors:  Andrew J Wiemer; Huaxiang Tong; Kelly M Swanson; Raymond J Hohl
Journal:  Biochem Biophys Res Commun       Date:  2006-12-21       Impact factor: 3.575

5.  A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.

Authors:  Yuri K Peterson; Patrick Kelly; Carolyn A Weinbaum; Patrick J Casey
Journal:  J Biol Chem       Date:  2006-03-03       Impact factor: 5.157

Review 6.  Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I.

Authors:  Kimberly T Lane; Lorena S Beese
Journal:  J Lipid Res       Date:  2006-02-13       Impact factor: 5.922

7.  Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition.

Authors:  Filippo Minutolo; Simone Bertini; Laura Betti; Romano Danesi; Gianbattista Gervasi; Gino Giannaccini; Adriano Martinelli; Anna Maria Papini; Elisa Peroni; Giorgio Placanica; Simona Rapposelli; Tiziano Tuccinardi; Marco Macchia
Journal:  ChemMedChem       Date:  2006-02       Impact factor: 3.466

8.  Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation.

Authors:  B S Gibbs; T J Zahn; Y Mu; J S Sebolt-Leopold; R A Gibbs
Journal:  J Med Chem       Date:  1999-09-23       Impact factor: 7.446

Review 9.  Lipid posttranslational modifications. Farnesyl transferase inhibitors.

Authors:  Andrea D Basso; Paul Kirschmeier; W Robert Bishop
Journal:  J Lipid Res       Date:  2005-11-08       Impact factor: 5.922

10.  Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase.

Authors:  Sarah A Reigard; Todd J Zahn; Kellie B Haworth; Katherine A Hicks; Carol A Fierke; Richard A Gibbs
Journal:  Biochemistry       Date:  2005-08-23       Impact factor: 3.162

View more
  5 in total

1.  A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.

Authors:  Komal M Sane; Michelle Mynderse; Daniel T Lalonde; Ivory S Dean; Jonathan W Wojtkowiak; Farid Fouad; Richard F Borch; John J Reiners; Richard A Gibbs; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

2.  Exploration of GGTase-I substrate requirements. Part 1: Synthesis and biochemical evaluation of novel aryl-modified geranylgeranyl diphosphate analogs.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2016-06-16       Impact factor: 2.823

3.  Electrophilic aromatic prenylation via cascade cyclization.

Authors:  John G Kodet; Joseph J Topczewski; Kevyn D Gardner; David F Wiemer
Journal:  Tetrahedron       Date:  2013-10-04       Impact factor: 2.457

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

Review 5.  Regulation of Small GTPase Prenylation in the Nervous System.

Authors:  Jairus M Reddy; Namrata G R Raut; Jennifer L Seifert; DiAnna L Hynds
Journal:  Mol Neurobiol       Date:  2020-01-27       Impact factor: 5.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.